811 results on '"Tanguay, Simon"'
Search Results
2. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)
3. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies
4. Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada
5. CT-based Bosniak classification of cystic renal lesions: is version 2019 an improvement on version 2005?
6. A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.
7. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers
8. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
9. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma
10. Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
11. MP36-13 ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY
12. PD16-03 UNDERSTANDING THE MOLECULAR CHARACTERISTICS AND VULNERABILITIES OF SARCOMATOID/RHABDOID RENAL CELL CARCINOMAS THROUGH INTEGRATIVE HISTOLOGICAL AND SPATIAL GENOMICS APPROACHES
13. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
14. Multimodal Prehabilitation to Enhance Functional Capacity Following Radical Cystectomy: A Randomized Controlled Trial
15. Achieving the “trifecta” with open versus minimally invasive partial nephrectomy
16. Making a case “against” focal therapy for intermediate-risk prostate cancer
17. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.
18. Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines
19. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies
20. Chapter 19 - The formation and the training of robotic surgeons
21. Proceedings From the 5th B2B Uro-Oncology: GU Cancers Triad Meeting: Prostate Cancer
22. Proceedings From the 5th B2B Uro-Oncology: GU Cancers Triad Meeting: Kidney Cancer
23. Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting: Bladder Cancer
24. The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors at Canadian academic centers
25. Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System
26. Adjuvant therapy for renal cell carcinoma
27. Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial
28. Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)
29. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence
30. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
31. Abstract B011: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas
32. Abstract B010: Germline susceptibility to renal cell carcinoma and implications for genetic screening
33. Abstract A012: Investigating the heterogeneity and clinical significance of tumor-associated macrophages in renal cell carcinoma milieu
34. Abstract PR005: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas
35. Needs Assessment Survey for the Management of Kidney Cancer
36. Management of complex renal cysts in Canada: results of a survey study
37. Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.
38. Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.
39. Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).
40. Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
41. Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
42. Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).
43. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions: Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board
44. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada
45. Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance
46. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions
47. Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population
48. MP41-03 IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE
49. PD07-10 OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC cT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE
50. Improving ultrasound-based prostate volume estimation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.